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Introduction: Functional Neurological Symptom Disorders (FNSD) are associated
with high levels of disability and immense direct and indirect health costs. An
innovative interdisciplinary rehabilitation approach for individuals with functional
neurological symptoms of motor type–Nocebo-Hypothesis Cognitive Behavioral Therapy
(NH-CBT)—combines CBT and movement retraining with video feedback embedded in
a comprehensive explanatory model of the etiology of FNSD.
Methods: This protocol describes the development and implementation of a phase
II, parallel group, randomized controlled trial with blinded outcome assessors to
compare the efficacy of NH-CBT with an active control condition (supportive counseling
and movement retraining). Individuals meeting diagnostic criteria of an FNSD or
psychogenic movement disorder will be randomly assigned to one of the 8-week
interventions. Self-report scales of motor and other physical symptoms, symptom-related
psychological variables, and assessor ratings of participants’ mobility will be administered
at baseline, and at 8- and 16-week follow-up. Adverse events will be monitored across
all sessions and therapeutic alliance will be measured at the end of therapy. The primary
statistical analysis will test the hypothesis that NH-CBT is more effective than the control
intervention at the 8-week follow-up.
Discussion: The therapeutic strategies of NH-CBT are theory-driven by assumptions
of the predictive coding model of the etiology of FNSD. Strengths and limitations of this
trial will be discussed.
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR;
identifier: ACTRN12620000550909).
Keywords: functional neurological symptom disorder, psychogenic movement disorder, cognitive behavioral
therapy, physical therapy, movement retraining, predictive coding model, randomized controlled trial,
nocebo effect
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INTRODUCTION

neurologists and neuropsychiatrists who are extensively
experienced in treating functional motor symptoms, proposed
to embed physiotherapy in a biopsychosocial framework
(16). This was a first attempt to move toward embedding
physiotherapy in psychological (mainly CBT-based),
interventions addressing dysfunctional illness beliefs, selfdirected attention, psychoeducation, and self-management
strategies (16). Non-controlled effectiveness trials of such
multidisciplinary treatment programs have demonstrated that
combining CBT-based and physiotherapy strategies could
be a promising approach for individuals with functional
motor symptoms. McCormack et al. (17) and Jacob et al. (18)
showed that participants’ motor symptoms, mobility, and daily
functioning significantly improved. Jordbru et al. (19) combined
in a 1-week treatment a physiotherapy intervention following
the principles of motor reprogramming (15) and embedded it in
psychoeducation and CBT strategies. However, the application
of CBT in these studies has generally focused on reducing
the stress caused by functional neurological symptoms, rather
than altering the underlying beliefs that may be causing the
symptoms. Moreover, whilst these previous interventions fit
the definition of a multidisciplinary approach (17, 18) or an
interdisciplinary approach (19), their strategies do not appear
to be integrated around a comprehensive theoretical framework
that clearly defines the mechanism behind functional symptoms.
The predictive coding model has become a valuable approach
to explain functional motor symptoms (20, 21). This model
describes body perceptions as the result of a continuous
process of generating, testing, and refining hypotheses of our
perceptual system. Learned knowledge about the world is
conceptualized as a set of neural representations or “priors”
in a hierarchical model. Incoming sensory inputs vary in
how well they match with existing priors. The resulting
“prediction error” depicts the proportion of input that is not
predicted by the prior. Our perceptual system constantly tries
to keep this prediction error as low as possible to maintain
homeostasis (22). Based on previous experiences a prediction
can be more or less “precise” or “strong,” depending on the
variance of its distribution. Edwards et al. (20) hypothesizes
that functional motor symptoms can emerge based on sensory
input (e.g., from a precipitating event or random discharges
of neuronal activity) that is afforded excessive precision and
strength by attentional processes. The motor symptoms are
maintained by the “overweighting of prior beliefs over sensory
data.” In accordance with the theory, clinical observations
often confirm that distraction can result in a normalization
of symptoms. Consequently, the precision of strength of the
abnormal prior should be reduced and it should no longer elicit
movements when attention is diverted. To our knowledge, there
has only one previous treatment been published, a specialist
physiotherapy for functional motor symptoms, that is based on
the predictive coding model. Nielsen et al. (23) showed moderate
effects of this treatment on health-related quality of life in a
feasibility RCT.
In contrast to Nielsen et al. (23), we developed an
interdisciplinary intervention, Nocebo-Hypothesis Cognitive
Behavioral Therapy (NH-CBT), that is unique regarding the

Symptoms of altered voluntary motor function that cannot
be explained by a neurological disorder are core features of
the motor type of Functional Neurological Symptom Disorder
(FNSD) (1), or Conversion Disorder as an official term
alongside FNSD, and psychogenic movement disorders (PMD)
(2). Weakness or paralysis, abnormal movements (e.g., tremor),
abnormal gait, and limb posturing are typical motor symptoms.
The incidence of persistent functional motor symptoms is
estimated to be 4–12/100,000 per year (3). People with functional
motor symptoms usually experience severe distress and disability
(4), comparable to those with progressive neurodegenerative
conditions (5). They are at increased risk of developing
comorbid mental health disorders (e.g., major depression,
anxiety disorders) (6) and of utilizing health-care resources at
high rates (7) resulting in increased direct costs to healthcare
systems and indirect costs based on work disability (4).
These epidemiological characteristics highlight the urgent
need for effective treatments. FNSD or PMD is one of the most
common diagnoses of new referrals to neurological services (8),
however over 50% of these individuals do not improve or even
feel worse at follow-up (9). There is currently no Class I evidence
supporting the efficacy of any treatment for functional motor
symptoms (10). The most promising evidence seems to come
from cognitive behavioral therapy (CBT) and physiotherapy
(11, 12). The central goal of CBT is to identify and modify
dysfunctional thinking patterns (e.g. ingrained core thoughts
about oneself or one’s body, somatic misinterpretations), linked
to the motor symptoms, and to promote behavioral changes. For
example, typical CBT strategies include psychoeducation (e.g.,
understanding mechanisms of symptoms), functional behavioral
analysis of symptom triggers, taking control of movements, and
training of assertive communication (13). In a pilot randomized
controlled trial (RCT), participants who underwent CBT tailored
for functional motor symptoms significantly improved in daily
functioning and secondary outcomes (14). The central goal
of physiotherapy is motor reprogramming (15). Usually a
systematic strategy is adopted that involves re-establishing
elementary movements in affected body regions and reinforcing
normal movement, while ignoring abnormal movements. More
complex motor tasks are added as soon as individuals are
able to perform simple movements appropriately, incrementally
approximating normal movement.
Similar to other syndromes of persistent physical symptoms
(e.g., chronic pain), mechanisms underlying functional motor
symptoms are assumed to be multidimensional and need
multidisciplinary interventional approaches. Accordingly,
the active ingredients of CBT and physical therapy should
be combined into a multidisciplinary approach to optimize
outcomes. A consensus recommendation by physiotherapists,

Abbreviations: CBT, cognitive behavioral therapy; DSM-5, 5th revision of
the Diagnostic and Statistical Manual of Mental Disorders; FNSD, Functional
Neurological Symptom Disorder; NH-CBT, Nocebo-Hypothesis Cognitive
Behavioral Therapy; PMD, psychogenic movement disorder; RCT, randomized
controlled trial; SAE, serious adverse events.

Frontiers in Neurology | www.frontiersin.org

2

December 2020 | Volume 11 | Article 586359

Richardson et al.

NH-CBT for Functional Motor Symptoms

way in which elements of psychological and physiotherapy are
combined. All disciplines involved in NH-CBT organize their
therapeutic input around the direct and transparent addressing
of illness beliefs as the primary target for their therapeutic
input. The nocebo-hypothesis (NH) part of NH-CBT is proposed
to be a crucial concept for the psychoeducation. The concept
of a nocebo effect can provide this essential conceptual link
between a “prior” and the motor symptom, in a way that
most people with FNSD can comprehend. Embedded in the
predictive coding model, a nocebo effect is explained as “negative
health-related changes in the mind-brain body unit” (24) that
are initiated and modulated by expectations (or “priors”). The
nocebo effect has originally been studied as a side effect reported
in the placebo arm of pharmacotherapy trials (25). Over time
the nocebo effect has been extended and has been used to
describe adverse effects of stimuli that individuals believe are
likely to have negative health effects, e.g., radiation emitted
by cell phones (26). Negative expectations can be generated
by external sources (e.g., explicit warnings of specific side
effects that can occur from a treatment) or just by increased
general awareness about the potential of a stimulus to cause
health problems (e.g., the belief of an individual that they are
especially sensitive to effects of a medication) (26). In people with
functional motor symptoms, a subconscious belief that there is
neurological damage affecting the function of parts of their body
is assumed to be a pathological mechanism. NH-CBT embeds
physical interventions in CBT strategies and has the singular
aim of disproving the (explicit and/or implicit) belief that the
person is neurologically damaged or diseased. In this sense, it
follows the traditional CBT’s concept of a behavioral experiment,
with the “evidence” invariably provided by video feedback in
this case.
Compared with previous treatments combining CBT
strategies and elements of physiotherapy for functional motor
symptoms, NH-CBT has four basic treatment principles that
all build on assumptions of the predictive coding model of
functional motor symptoms:

The central aim of this RCT is to investigate if NH-CBT
for participants with persistent functional motor symptoms
is more effective in improving physical functioning (primary
outcome) (hypothesis 1) and secondary outcomes (hypothesis
2) in comparison to an active control intervention at the
end of therapy. We will also examine if treatment effects
can be maintained over 8 weeks post-intervention (hypothesis
3). Participant characteristics at baseline will be investigated
as moderator variables of the intervention effect on an
exploratory basis.

METHODS AND ANALYSIS
Setting, Participant Recruitment, and
Eligibility Criteria
The study will be conducted at the ISIS Centre, a rehabilitation
ward of Wakari Hospital (Dunedin, New Zealand), where
people with neurological conditions undergo outpatient and
inpatient treatment. Participants will be referred by neurologists
from the Neurology Department at Dunedin Public Hospital
(Southern District Health Board). The ISIS Centre is part of
the Southern District Health Board of New Zealand and covers
the neurological rehabilitation of 7% of the country’s population
(∼337,000 people).
The inclusion criteria will be:
a) Aged 18 or older
b) New or returning patients presenting to the participating
Neurology Department
c) Diagnostic investigations by a neurologist including the
appropriate medical examination have been completed.
d) Diagnostic investigations resulted in a diagnosis of FNSD
with abnormal movement according to diagnostic criteria of
DSM-5 (1) or of a PMD according to the diagnostic criteria by
Gupta and Lang (2). Acute (<6 months) as well as persistent
symptom presentations (≥6 months) will be accepted.
e) The symptoms cause clinically significant distress or
impairment in social, occupational, or other important areas
of daily functioning.

a)

Participants have to understand the role of their “priors” or
beliefs as the key mechanism behind their symptoms.
b) It is essential to provide the participants with new and
precise “motor input” to lower the precision and strength of
their abnormal prior beliefs, to develop a new belief, and to
help increase the precision and strength of this new belief.
c) The precision of the new motor input can be further
increased and the abnormal prior belief should be modified
by promptly providing participants with visible feedback
about their movements.
d) Participants’ attention has to be diverted to lower its
precision-increasing effect on abnormal priors.

Exclusion criteria will be:
a) Diagnosis of a complex regional pain syndrome, Dissociative
Identity Disorder, or Posttraumatic Stress Disorder of high
severity with significant dissociation
b) Severe mental health disorder requiring inpatient mental
health treatment or potentially affecting trial participation
(e.g., suicidality, acute psychosis, active or extensive selfharm)
c) Receiving concomitant psychological intervention that
targets motor symptoms
d) Initiation or change in regimen of psychopharmacotherapy at
any time between 4 weeks before baseline assessment and the
final follow-up assessment
e) Presence of significant physical trauma/comorbid health
conditions (e.g., significant musculoskeletal injuries, severe
respiratory illness) precluding participation in our movement
retraining (we will include participants who are diagnosed

Richardson et al. (27) previously examined the effects of NHCBT in a retrospective case series design without a control group.
The authors examined the effect of the treatment protocol in
12 patients with either weakness/reduced mobility, or tremor,
or non-epileptic seizures, or mixed symptoms. In seven of the
12 episodes a clinically reliable and significant change of the
functional motor symptoms was reached.
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neurological conditions, as long they have individual
symptoms that are considered to have a high degree of
certainty that they are functional)
f) Low English language proficiency
g) Inability to provide informed consent to participate in
the trial

procedure is summarized in Figure 1. This protocol has
been developed according to the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) (see
Supplementary Material) (28).
A consultant neurologist will assess participants who
are consecutively admitted by the participating Neurology
Department using the diagnostic criteria of a FNSD (1) or
PMD (2). During the neurological assessment, participants will
undergo a clinical interview and necessary medical investigations
and tests to help establish the diagnosis. The neurological
assessment will include an interventional component: the
neurologist will give participants a standardized explanation
of FNSD/PMD (see Interventions). This explanation will
follow suggestions by Stone (29). It will include elements
such as emphasizing the mechanism of the symptom rather
than the cause, explaining how the diagnosis was made,
reassuring participants that their symptoms are common,
emphasizing the reversibility of their symptoms, and introducing
self-help as a key component of a successful treatment. It
will be explained how depression and anxiety affect and
can perpetuate their motor symptoms. Neurologists will be
encouraged to use metaphors as part of their explanations.
Individuals who appear to be eligible to participate in the
trial will then be informed by the neurologist about the

Functional neurological symptoms are associated with increased
rates of comorbid mental health disorders (6). In order to
obtain a representative sample, individuals with comorbid
mental health conditions (e.g., depression) or other functional
(non-motor) symptoms will be included as long as the other
condition/symptoms do not require inpatient mental health
treatment or potentially affect trial participation (see exclusion
criterion b).

Study Design and Procedure
This is a randomized, parallel group, phase II, assessorblinded, superiority trial comparing the efficacy of a
NH-CBT with an active control intervention in individuals
with persistent functional neurological symptoms of
motor type. Depending on their symptom status at 16week follow-up, participants in the control group will
be offered a delayed NH-CBT treatment. The study

FIGURE 1 | Flow chart of the study procedure and outcome assessments (NH-CBT, Nocebo-Hypothesis Cognitive Behavioral Therapy).
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envelopes. The principal investigator (MR) and therapists
involved in the study will not be masked to the results of the
randomization, however the outcome assessors will be blinded to
minimize detection bias. Before each of the follow-up interviews,
participants will be clearly instructed not to discuss treatment
content or the identity of their therapists with their assessor.
After each follow-up assessment, the blinding of the outcome
assessor will be checked with several self-report items (e.g.,
“Please guess which condition the participant was in”). In the case
that the blinding of an outcome assessor cannot be ensured, the
three assessor-rated measures will be re-done by a fully blinded
assessor. Individual rehabilitation staff will deliver only one of
the interventions, either NH-CBT or the control treatment, to
reduce the risk of contamination bias. Participants from different
treatment groups will not be treated in the same room/gym at the
same time. Most of our participants will undergo an outpatient
treatment and it will be less likely that we have several patients
with FNSD receiving inpatient treatment at the same time. It is
therefore less likely that participants will communicate with each
other about the course of their treatment. Inpatient participants
will be instructed not to discuss the details of their treatment with
other patients, and inpatient rehabilitation staff will be instructed
to remind inpatients of this. To minimize reporting bias the study
is registered and all pre-specified outcomes are published under
the Australian New Zealand Clinical Trials Registry (ANZCTR;
identifier: ACTRN12620000550909). To minimize bias due to
loss to follow-up participants will be sent text reminders on the
morning of their appointments. Participants will be considered a
dropout when they miss more than two sessions without calling
first. Travel costs are not provided directly by the trial but can
be reimbursed by other agencies under certain circumstances.
Participants will be supported in accessing these reimbursements
when eligible.

trial. The neurologist will seek participants’ permission to be
contacted by the principal investigator (MR) to attend the
psychological assessment.
The first part of the psychological assessment is a clinical
interview where the principal investigator (MR) will provide
individuals interested in participating with more detailed
information about the study. We will explain to potential
participants that we will offer them one of two treatments:
one is conventional and more commonly used for individuals
with FNSD, and has been found to be effective; and the other
is new, and we are yet to establish evidence of its efficacy.
Participants will be blinded to details of the content and proposed
mechanisms of NH-CBT and the control treatment, and to
differences between both treatments. They will only be informed
that the core component of both treatments will be movement
retraining, delivered by a rehabilitation professional. During the
first part of the psychological assessment we will assess whether
individuals meet all eligibility criteria and will ask them to give
written consent to participate. In the second part, an assessor
who is independent of this study and trained in applying the
assessment tools will do the baseline assessment. The research
assistant will do the Simplified Functional Movement Disorder
Rating Scale (S-FMDRS) (30), the Functional Mobility Scale
(FMS) (31) and the 10 m-Walk Test (32) with the participant.
A physiotherapist will be present to ensure the safety of the
participant. Participants will complete a baseline questionnaire
including questions about demographic variables and all other
outcome measures (see Outcomes and Assessments).
Participants will then be randomly assigned to receive either
NH-CBT or the active control treatment over the following 8
weeks. At the end of the intervention period (8-week follow-up)
participants will attend another assessment with an independent,
blinded assessor and will complete all outcome measures.
Sixteen weeks after baseline, participants from both groups will
complete all outcome measures again (16-week follow-up). At that
point, participants in the control group who have not achieved
symptom remission will be offered NH-CBT and will be asked
to complete a final questionnaire after 8 weeks of treatment
(24-week follow-up).
The authors have planned qualitative interviews at the posttherapy stage with the first 10 patients from either arm of
the trial, plus all patients identifying as Māori, to elucidate
participants’ experiences of their treatment and understanding
of their symptoms, and to investigate the acceptability and
feasibility of the trial processes and cultural influences on patients
perception of treatment.

Data and Patients’ Safety Monitoring
Participants with any type of neurological diagnosis with a
range of associated physical disabilities (e.g., weakness, balance
difficulties) are at some risk of falling. According to clinical
observations, people with FNSD/PMD are at lower risk of
injury than people with neurological damage (16). However,
there are still some incidents with this group. Treatment
necessarily involves taking managed risks whilst ensuring
safety, using management strategies and mobility aids. All trial
participants will be assessed by a physiotherapist as they start
the movement retraining part of the treatment (see Interventions)
and throughout the treatment if needed, to ensure adequate steps
are taken to ensure safety. In the case of serious adverse events
(SAE) the Severity Assessment Code (SAC) rating for adverse
event reporting (33) will be completed by the therapist. The study
therapist has to contact the principal investigator (MR) within
24 h after the event. The PI will not be blinded to the result of the
randomization and will therefore be able to decide if the SAE was
a serious adverse reaction to the trial treatment.
In order to monitor and supervise the progress of the trial
and SAEs associated with the trial treatment, an independent
Data Safety and Monitoring Board will be involved, including
a psychiatrist, a statistician, a manager of the ISIS Centre and

Methods for Minimizing Bias
To minimize selection bias eligible participants will be randomly
assigned to either the NH-CBT or the active control group in
a 1:1 ratio using a block randomization strategy (8 blocks with
20 and 1 block with 12 participants). Randomization will be
conducted by a research associate not affiliated with the study.
The randomization scheme will be generated by using the website
randomization.com which applies a pseudorandom number
algorithm (http://www.randomization.com). Group allocation
will be provided in sealed opaque sequentially numbered
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motor symptoms can be explained by a strong mental
representation of their body or parts of their body as
neurologically damaged or diseased. The key component
of this treatment is to retrain participants’ symptom
processing and to reduce the strength of this mental
representation. The following four key strategies of NHCBT are essential to address the four basic treatment principles
mentioned earlier:

a person who was formerly treated for FNSD at ISIS as a
stakeholder of patients’ interests. The DSMB will meet on a
regular basis and will make final decisions to terminate the trial
prematurely for harm, based on their monitoring and evaluation
of SAE attributed to our treatment. The SAC rating for adverse
event reporting allows for differentiation of four levels of severity
of adverse events (34). In the case of severe and major events
(SAC 1 and 2), the trial would have to be suspended with
immediate effect pending investigation. The DSMB will discuss
SAC 3 and 4 events (minor to moderate events), how they
relate to our treatment and how they will influence the further
course of this trial. The DSMB will also make final decisions to
terminate the trial prematurely for benefit, based on stopping
rules and interim analyses described below (see Sample size,
power calculations, and interim analyses).

a) To help participants to understand the role of their “priors”
or beliefs as mechanisms causing their symptoms and to
remind them about the neurological evidence for a lack of
neurological damage or disease (i.e., what is not causing their
symptoms), the concept of the “nocebo effect” is explained
and used to inform a cognitive behavioral formulation which
explains their symptoms. The psychoeducation component of
NH-CBT shall provide the individual with a new, alternative
belief (i.e., what is causing their symptoms).
b) The movement retraining strategies are used in the sense of
a behavioral experiment. They are essential to provide the
participants with new and precise “motor input” to lower
the precision and strength of their abnormal prior beliefs.
The therapist and participant will continue reflecting on
the change of “priors” and beliefs during the movement
retraining as being the only possible mechanism behind
any improvement.
c) This process is video-recorded, and feedback is promptly
given to the participant that any normalized movement
is evidence confirming the nocebo explanation for
their symptoms and disconfirming the presence
of neurological damage.
d) To divert participants’ attention and to lower the precisionincreasing effect on abnormal priors, they have to be
distracted while they practice movements.

Interventions
Structure, Providers, and Treatment Fidelity
Participants in both study groups will first receive an explanation
of their functional motor symptoms by their neurologist, as
part of the neurological assessment (described earlier under
Study Design and Procedure). The main part of the intervention
in both groups will start with an initial 60–90 min session
that includes education of participants. In both groups, this
initial session will be followed by a minimum of 2 up to a
maximum of 23 sessions of movement retraining and one
final session of relapse prevention. Differences between the
groups in the content of the initial session, the movement
retraining and the relapse prevention are described below.
Sessions will last between 30 and 120 min and will be delivered
face to face over 8 weeks. The frequency and scheduling will
depend on participants’ individual needs (e.g., type and severity
of symptoms) and stamina. (see Criteria for finishing the
movement retraining before a maximum of 23 sessions can be
found in Table 1 under “8. When and how much”. Sessions
will follow a treatment manual and will take place either as an
inpatient or an outpatient treatment. For both interventions, the
initial education session will be conducted by a licensed clinical
psychologist, and the movement retraining will be delivered
by a licensed rehabilitation professional (physiotherapist,
occupational therapist, rehabilitation assistant), but will
necessarily involve physiotherapist oversight and involvement
at some point. Gender, age, professional backgrounds, and
years of experiences of the neurologists, clinical psychologists,
and rehabilitation professionals delivering the NH-CBT and
the control intervention will be recorded in the main trial
paper. Table 1 outlines details of Nocebo-Hypothesis Cognitive
Behavioral Therapy (NH-CBT) and the active control treatment
(supportive counseling and movement retraining), as well as the
means of ensuring treatment fidelity, according to the TIDieR
checklist (37).

Supportive Counseling and Movement Retraining (Active
Control Intervention)
The control intervention was designed to control for the
non-specific effects of (a) education about symptoms, (b)
emotional support from a therapist, and (c) movement
retraining. For (a), the psychologist will reassure the participant
that symptoms are not caused by structural damage or a
degenerative process, however there will be no conversation
about beliefs or expectations being an important factor in the
development and maintenance of functional motor symptoms.
The concept of a nocebo effect will not be mentioned. The
psychologist will mainly repeat the explanation of FNSD/PMD
by Stone (29) that will have already been provided by the
neurologist during the initial neurological assessment. For (b)
the psychologist will provide supportive counseling about the
participants’ symptoms and associated distress and everyday
impact, and strategies to manage distress such as relaxation
exercises. For (c), motor symptoms will be conceived of as
learnt patterns of movement that are outside participants’
control. The movement retraining will attempt to re-establish
normal movement patterns, but without video feedback and
distraction techniques.

Key Strategies of and Differences Between NH-CBT
and the Active Control Treatment
NH-CBT
The NH-CBT program builds on the predictive coding
theory of FNSD/PMD (20). It is assumed that participants’
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TABLE 1 | Nocebo-Hypothesis Cognitive Behavioral Therapy and supportive counseling and movement retraining (active control intervention) described following the
TIDieR checklist.
Items TIDieR
checklist
1. Name

Nocebo-Hypothesis Cognitive Behavioral Therapy (NH-CBT)

Supportive counseling and movement retraining

2. Why

The current intervention is based on a predictive coding theory of
FNSD/PMD. This theory highlights the following key mechanisms of
functional motor symptoms: Pre-disposing factors (e.g., past events
experienced or witnessed that lead the person to doubt the integrity of their
neurological system) lead to a mental representation of their body/parts of
their body to be neurologically damaged or vulnerable to neurological
damage, dysfunction or disease. When triggered by a specific situation
(e.g., that strongly confirms that belief), neurological functioning starts to
change creating physical symptoms.

The control intervention is designed to control for the non-specific
effects of (a) education about symptoms, (b) emotional support from a
therapist, and (c) movement retraining. The intervention is based on a
model of sequential motor learning (16). This model assumes that
movement can be retrained or “reprogrammed” by utilizing a sequential
approach to re-establish more normal movement patterns.

3. What
(materials)

Information for Neurologists: Neurologists will receive written information about a standardized explanation of FNSD/PMD, following suggestions by
Stone (29) (emphasizing the mechanism of the symptom rather the cause, explaining how the diagnosis was made, emphasizing that it is common,
emphasizing reversibility, that self-help is essential for recovery, the possible effect of depression and anxiety on symptoms, and the use of
metaphors).
Worksheet: Written information about the diagnosis and treatment will be
provided to participants in the initial educational intervention, to supplement
the verbal explanations. This sheet will outline the “nocebo hypothesis”
regarding functional symptoms, including information about the concept of
subconscious processing and the placebo/nocebo effect, as well as
affirming much of the information given by the neurologists. The description
of the treatment will deliver more information about the movement
retraining, including video feedback.

Worksheet: Written information about the diagnosis and treatment will
be provided to participants in the initial educational intervention, to
supplement the verbal explanations. This sheet will contain information
similar to that outlined by the neurologists (see TIDieR Checklist item 3),
as well as the basic information about the physical therapy component
of the treatment program.

Intervention manual: Each therapist in the experimental condition will receive
a NH-CBT manual that complements the NH-CBT training and contains
background information about FNSD/PMD, a guide to using the treatment
manual, and a detailed description of each of the treatment components
with examples of wording.

Intervention manual: Each therapist in the control condition will receive
a manual describing the supportive counseling and movement
retraining, containing a guide to using the treatment manual, a detailed
description of each of the treatment components with examples of
wording, and information about what content should be avoided (e.g.,
explaining the nocebo effect and the role of beliefs as mechanisms of
the symptoms).

Portable electromyography biofeedback unit and tablet to provide video
feedback

Since the control intervention does not include video feedback or any
other form of visual feedback, no tablet or electromyography
biofeedback unit is provided.

Additional materials such as mobility aids (e.g., walking frame), parallel bars, treadmill, etc. may be required depending on the participant’s needs
4. What
(procedures)

Neurological assessment: Participants in both study groups will be assessed by a neurologist prior to be enrolled in the trial. The
neurologists will provide the participant with a standardized explanation of FNSD/PMD (see TIDieR Checklist item 3).
NH-CBT psychoeducation (1 session): Understanding the diagnostic
evidence: Therapists are asked to study participants’ health records to gain
objective evidence for the FNSD/PMD diagnosis and to identify any
historical reasons why someone might believe that they are susceptible to
the symptoms they are presenting with (including past medical events, the
onset, and course of symptoms).
Assessment: The main goal of this part of NH-CBT is to explore
pre-disposing factors and triggers of functional motor symptoms from
participants’ subjective point of view.
Transparent sharing of the nocebo hypothesis: This treatment component
addresses participants’ personal beliefs about the causes of their
symptoms, and their understanding of the terms “subconscious” and
“placebo/nocebo effect” (using a graphical aid and metaphors to explain the
effect of expectations and belief that a medication works) is explored. A
psychological formulation is shared with the participants that incorporates
presenting motor symptoms within a hypothesis that symptoms are due to
a “nocebo effect.” The aim is to engender in the participant an alternative
belief about their symptoms, to challenge the one currently held. The
therapist rounds up this component with framing the role and goals of the
movement retraining within the nocebo hypothesis.

Psychological input and supportive counseling (1 session): The first
session of the active control intervention includes elements of a
treatment protocol by Nielsen et al. (30).
Assessment: The participant’s symptom history is assessed regarding
current symptoms and health-related problems, symptom onset,
predisposing/precipitating/perpetuating factors, symptoms’ impact on
daily life, previous experiences with treatments and health care
professionals, and exploration of participants’ understanding of their
symptoms and their cause.
Education: The therapist reiterates the education about FNSD/PMD
that was given earlier by the diagnosing neurologist according to the
suggestions by Stone (29). The therapist will ensure that the person
knows that symptoms are not caused by structural damage or a
degenerative process. Then a brief symptom model of FNSD/PMD is
provided that conceptualizes functional motor symptoms as a result of
a fight or flight (survival) response and secondary behavioral changes
(e.g., avoidance behaviors) causing disability.
Supportive counseling: The therapist uses active listening and
supportive counseling skills (e.g., conversation about coping strategies,
impact of symptoms on family, and work) but should not adopt a
structured therapy approach.
(Continued)
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TABLE 1 | Continued
Items TIDieR
checklist

5. Who
provided

NH-CBT movement retraining with video feedback (2–23 sessions): The
participant is then given opportunities to physically experience themselves
as functioning better. The movement retraining is individualized, according
to participants’ symptoms and needs. The intervention manual proposes
exercises for different forms of functional motor symptoms (e.g., functional
weakness, balance, tremor, abnormal gait/jerks/myoclonus/involuntary
movements, or fixed dystonia). The exercises function as behavioral
experiments, to demonstrate to participants that their brains and bodies are
capable of working better/normally under certain circumstances. This
variability is interpreted to be almost always a sign that there is no damage
or disease causing the symptoms. Therapist and participants repeatedly
reflect that any improvements can only be due to a change of belief, thus
strongly suggesting that belief is the mechanism behind the symptoms.
Distraction: Distraction, or varying participants’ attention to other stimuli, is
an important principle of the NH-CBT movement retraining and is almost
always the way to create this momentarily improved functioning. A
distractor is previously selected collaboratively by therapist and participant
(e.g., their favorite music) and is presented whilst participants engage in
relevant physical movement.
Video recording/feedback: Another important element of the NH-CBT
movement retraining is video recording and immediate video feedback if the
participant shows improved movement when distracted. Improved
functioning seen on video feedback is framed as evidence that the “nocebo
hypothesis” is valid: symptoms are not caused by structural neurological
damage and their bodies are more capable than participants previously
believed. More physical activity is then attempted, with further video
feedback, and this treatment cycle is repeated, attempting more, and more
complex activity as the participant improves.
Purposeful optimism: Throughout treatment, therapists will be specifically
instructed to portray as much optimism as possible to the participant about
potential recovery, e.g., talking about how many people have got better
using this treatment.

Control movement retraining (2–23 sessions): The movement retraining
part of the control intervention is based on a sequential motor learning
approach proposed by a consensus recommendation for
physiotherapy for functional motor disorders (16). The main rationale
for movement retraining is that FNSD/PMD can be conceived of as
unwanted patterns of movement that have been subconsciously
programmed and learned, and are outside the person’s control. It is
assumed that these patterns cause symptoms and that symptoms are
perpetuated by secondary changes. Movement can be
retrained/“reprogrammed” by utilizing a sequential approach to
re-establishing more normal movement patterns.
Assessment: The assessment includes determining levels of falls risk,
methods of keeping the person safe, observation of the impact of
symptoms on posture and movement, exploring the nature of
symptoms, evaluation of any potential compensatory strategies, and
exploring possible secondary physical changes.
Sequential approach to restore normal movement patterns: Elementary
symptom free components of movement are established, and built on
in successive stages to gradually reshape normal movement patterns.
Another target is to change maladaptive compensatory habitual
postures, movement patterns, and behaviors. Finally, secondary
changes (e.g., physical changes such as deconditioning or changes of
social/occupational roles) are addressed. Different movement retraining
strategies are provided for different forms of functional motor
symptoms in the treatment manual.
Therapists are asked to avoid mentioning concepts such as
nocebo/placebo effects, beliefs, or expectations. No visual feedback
(neither video nor mirror feedback) is used. External distractors (e.g.,
music, irrelevant conversation) to vary participants’ attention are not
allowed. Purposeful optimism should not be part of
therapists’ approach.

NH-CBT relapse prevention (1 session): The treatment cycle is taken as far
as possible in the final session. Therapist and participant collaboratively set
a final movement goal that is as high as the participant wishes. The
participant then tries to achieve it. The second part of the relapse prevention
stage gives clear advice to people about what to do if symptoms re-emerge
in future. For each individual person, a personalized behavioral experiment
is devised that will prove to participants that their most feared neurological
event is not happening. This experiment involves them reminding
themselves that minor transient symptom, often referred to as “glitches”, are
harmless and are just the subconscious expressing a momentary doubt via
a nocebo effect.

Control relapse prevention (1 session)
A self-management plan is introduced to the participant, including a
summary of useful strategies that help to normalize movement, activity
plans to address boom and bust patterns and how to progress activity,
future goals, and what to do on difficult days and during periods of
symptom exacerbation. Therapists are instructed to avoid making any
suggestions that state or imply the role of illness beliefs.

Neurological assessment: All neurologists involved in this trial will be employed on consultant level. They will receive training from the PI (MR) in
person or by telephone. They will have been given suggestions by Stone (29) of how to explain FNSD/PMD to participants.
NH-CBT psychoeducation: clinical psychologist (PI: MR)

Psychological input and supportive counseling: clinical psychologist
(other than PI)

NH-CBT movement retraining: licensed rehabilitation professional
(physiotherapist, occupational therapist, rehabilitation assistant), with a
physiotherapist always having a role in developing the treatment plan
(including safety management plan) and having oversight of the physical
elements of the treatment

Control movement retraining: licensed rehabilitation professional
(physiotherapist, occupational therapist, rehabilitation assistant), with a
physiotherapist always having a role in developing the treatment plan
(including safety management plan) and having oversight of the
physical elements of the treatment

Multi-disciplinary staff members delivering the initial educational or movement retraining intervention will have received training from the principal
investigator (MR) which can take between 0.5 and 1 day (depending on the professional’s level of experience). Each staff member will be trained
either in NH-CBT or in the control intervention. We will use a brief checklist to ensure that the rehabilitation professional has demonstrated an
understanding or proficiency in delivering the key ingredients of the intervention. All staff members involved in this trial will receive a comprehensive
treatment manual. All professionals who deliver treatment within this trial are required to attend supervision frequently with a licensed supervisor
experienced in CBT for individuals with functional neurological symptoms. The initial therapy session will be recorded. The supervisor will give
immediate feedback to the therapists (of the control group in particular) in case they would expose participants to distraction techniques or
interventions that address illness beliefs. At least one supervision session will be planned for every intervention participant treated.
(Continued)
Frontiers in Neurology | www.frontiersin.org

8

December 2020 | Volume 11 | Article 586359

Richardson et al.

NH-CBT for Functional Motor Symptoms

TABLE 1 | Continued
Items TIDieR
checklist
6. How

All sessions will be delivered as individual sessions in a face-to-face format as part of either an inpatient or outpatient treatment.

7. Where

The majority of sessions will occur at the ISIS (Rehabilitation) Centre, Wakari Hospital, Dunedin, for both inpatient and outpatient
treatment, although some sessions will occur in community settings for some participants, predominantly when they are in the latter
stages of treatment.

8. When and
how much

1 neurology session (30–50 min)
1 initial session of education (60–90 min)
Minimum 2 up to maximum 23 NH-CBT or control movement retraining sessions (30–120 min) over 8 weeks
1 session of relapse prevention (30 min)
Participants can stop therapy before the 25 h limit if they (a) subjectively consider themselves to be fully recovered, (b) can mobilize at
5.0 km/h on a treadmill for 15 s, and (c) had at least one initial psychoeducation session and 2 sessions of movement retraining. These
criteria are consistent with the suggestion by an international Functional Neurological Disorders Core Outcome Measure Group (35).

9. Tailoring

The intervention is standardized by a treatment manual. The manual describes opportunities of how the education at the beginning can be
tailored according to participants’ individual functional motor symptoms and problems. The movement retraining session tasks and
training will be adapted according to participants’ individual symptoms. However the rehabilitation professionals are encouraged to focus
on the key principles of the treatment.

11. How well
(planned)

All therapists in this trial must adhere to a therapy manual and receive training in the treatment content and procedure. Therapists are
required to attend supervision frequently with a licensed supervisor experienced in CBT for individuals with functional neurological
symptoms.
Treatment fidelity will be assessed as follows: All initial therapy sessions will be audio-recorded. A checklist of key treatment objectives and
principles will be used to assess treatment fidelity and its two components, therapist adherence and treatment specificity, for both the
NH-CBT and the active control intervention. We will assess therapist competence with a validated rating scale [e.g., Cognitive Therapy
Scale (36)]. Session records of a randomly selected sample (30% of the intention-to-treat sample) will be rated by two independent,
blinded raters.

Item 10 (Modifications: If the intervention was modified during the course of the study, describe the changes) and 12 (How well [actual]: If intervention adherence or fidelity was assessed,
describe the extent to which the intervention was delivered as planned) of the TIDieR Checklist do not apply to our trial and are omitted from this table.

of life is classified as one of the most relevant outcome domains in
clinical trials with individuals with persistent somatic symptoms
and FNSD/PMD in particular (38). The internal consistency
is high (Cronbach’s alpha = 0.90) (40). All secondary outcome
measures are summarized in Table 2. The use of the EuroQol-5
Dimension Questionnaire (EQ-5D-5L) will allow us to compare
our intervention and control treatment regarding different health
economic indices (e.g., Disability-Adjusted Life Year [DALYs] or
Quality-Adjusted Life Years [QALYs]). Different dimensions of
healthcare utilization, assessed with the Client Service Receipt
Inventory (CSRI) and from participants’ electronic health
records, will allow us to measure further cost signals.

The active control intervention will not address any of the key
treatment strategies of NH-CBT. The active control intervention
will differ from the NH-CBT regarding the following aspects:
a) It will not include any discussion of the concept of the
“nocebo effect” or the role of beliefs as mechanisms of
functional motor symptoms.
b) The movement retraining will not be used in the sense of
a behavioral experiment, but as a systematic attempt to reestablish normal movement.
c) It will not involve any means of visual feedback.
d) It will not use any engrossing, external distractors, such
as music, video, video games, irrelevant conversation, or
counting. The only redirecting of attention will involve a
suggestion that the participant focus on a point in space,
instead of on their bodies.

Data Management and Statistical Methods
Data Management and Dropout From Study
In order to enter all variables defined in the study protocol,
standardized electronic case report forms will be prepared and
administered. All questionnaires will be set up electronically
and administered on a laptop. Data entry will only allow values
in a valid range. Prior to data analyses, data will be checked
for plausibility.
In this trial two different kinds of dropout will be defined: a
study dropout and therapy dropout. A study dropout is defined
as a participant who misses at least one of the main assessments
(baseline, 8- or 16-week follow-up, see Figure 1). A therapy
dropout is defined as a participant

Outcomes and Assessments
The choice of primary and secondary outcome measures was
based on the recommendations of the Functional Neurological
Disorder-Core Outcome Measures Group (35) and the European
Network of Somatic Symptom Disorders (38). The primary
outcome and endpoint will be the 36-item Short Form Health
Survey (SF-36) Physical Functioning subscale at 8-week followup (39, 40). DSM-5 has shifted the focus of classification
from the assessment of somatic symptoms to the consideration
of concurrent psychosocial impacts (1). This 10-item Physical
Functioning subscale assesses a range of severe and minor
physical limitations during a typical day. Health-related quality
Frontiers in Neurology | www.frontiersin.org
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TABLE 2 | Assessments, outcomes, and measures.
Outcome domain

Measure

B

8-w
FU*

16-w
FU

24-w
FU

Short Form-36 Health Questionnaire (SF-36), Physical
Functioning subscale (39)

x

x

x

x

Functional motor symptoms

Simplified Functional Movement Disorder Rating Scale
(S-FMDRS)* (30)

x

x

x

x

Fatigue

Short Form-36 Health Questionnaire (SF-36), Vitality
subscale (39)

x

x

x

x

Somatic symptom severity

Patient Health Questionnaire-15 (PHQ-15)

x

x

x

x

Primary outcome measure
Physical functioning
Secondary outcome measures
Somatic symptoms

Illness consequences
Mobility

10 m-Walk Test* (32)

x

x

x

x

Functional Mobility Scale (FMS)* (31)

x

x

x

x

Symptom disability

Modified Pain Disability Index (PDI) (41, 42)

x

x

x

x

Health-related quality of life

Short Form-36 Health Questionnaire (SF-36) (39)

x

x

x

x

Quality of Life

EuroQol-5D (EQ-5D-5L) (43)

x

x

x

x

Health care utilization (past
3 months)

Item 7 and 8 of the modified Client Service Receipt
Inventory (CSRI) for chronic pain patients (44, 45)

x

x

Health care utilization

Participants’ electronic health records

x

x

Anxiety

Generalized Anxiety Scale-7 (GAD-7) (46)

x

x

x

x

Depression

Patient Health Questionnaire-9 (PHQ-9) (47)

x

x

x

x

Catastrophic thinking about
symptoms

Symptom Catastrophizing Scale (SCS) (48)

x

x

x

x

Psychological features

Illness perception

Brief Illness Perception Questionnaire (BIPQ) (49)

x

x

x

x

Dissociation

Brief Dissociative Experiences Scale (B-DES) (50, 51)

x

x

x

x

Participant satisfaction
Therapeutic alliance

Work Alliance Inventory—Short Form (WAI-SR) (52)

x

Participant’s perception of
change

Clinical Global Impression Scale of Improvement (CGI-I)
(53)

x

Adverse events in therapy

Inventory for the Assessment of Negative Effects of
Psychotherapy (INEP) (54)

x

Adverse events in therapy

Severity Assessment Code rating for adverse event
reporting (SAC)† (33)

x
x

x

Adverse events
x

*Blinded assessor rating. † The SAC will be applied during the 8 weeks of NH-CBT in case of serious adverse events.

Sample Size, Power Calculations, and Interim
Analyses

b) who stops therapy after the minimum number of sessions
but before the therapy goal has been reached (typical reasons:
low therapy adherence, external factors such as moving
away, etc.), or
c) who no longer meets eligibility criteria (e.g., due to change in
regimen of psychopharmacotherapy).
The reason for dropout must be
therapist. Even if participants drop
or become non-eligible during
therapy, they will be encouraged
follow-up assessments.
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The power analysis for our trial was run with G∗ Power 3.1.9.4. In
a previous trial, a physiotherapy for functional motor symptoms
reached a moderate effect (f = 0.33) at 6-month follow-up
on the SF-36 Physical Functioning subscale, our primary
outcome (23). For this trial we conservatively assume a small
group∗ time interaction effect (f = 0.10) under consideration of
our three measurements and a test-retest reliability of r = 0.5.
A power analysis for a mixed-effect ANOVA with an alpha error
probability of 0.05 and a power of 0.80 results in an optimal total

documented by the
out of the treatment
the course of the
to complete further
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Trials (58), we will compare the distribution of participants with
an improvement of at least 30 or 50%, no change, or deterioration
on the primary outcome between the study groups with χ 2 tests. Groups will be compared regarding adverse therapy effects,
measured with the Inventory for the Assessment of Negative
Effects of Psychotherapy, with independent sample t-tests and
χ 2 -tests. To assess interrater reliability of the treatment fidelity
ratings, intraclass coefficients (two-way random model with
measure of agreement) for each item will be computed.

TABLE 3 | P-values (based on Lan-DeMets alpha spending function) indicating a
necessary stop of the trial and needed sample size at each interim analysis.
Interim analysis

Sample size

P-value

1

22

0.00000003

2

44

0.00009

3

66

0.001

4

88

0.005

5

110

0.013

6

133

0.024

7

155

0.036

8

172

0.050

DISCUSSION
The central aim of this RCT is to examine the efficacy of
an innovative interdisciplinary treatment for individuals with
functional motor symptoms. We aim to combine CBT- and
physiotherapy-based strategies not just in a cumulative sense
but by intertwining their mechanisms and by embedding them
within a singular coherent theoretical framework, the predictive
coding model of FNSD (20). For example, we will use a
movement retraining to boost the effect of psychoeducation
and cognitive restructuring to establish new functional symptom
beliefs by regularly reflecting with the participants on the
role of beliefs during the movement retraining and providing
the participant with the behavioral evidence of normal and
healthy movement.
We plan a randomized trial implementing an active control
intervention that is designed to control for non-specific effects
of education, emotional support, and movement retraining. A
strength of this trial is that we will be able to gain a controlled
assessment at the end of treatment and 8 weeks later. Another
strength of this design is the mixed method approach, including
clinician-rated, observer-based, and patient-reported outcomes.
Blinded assessors will help to reduce the risk of detection bias.
Besides the strengths, we anticipate several limitations. We
have already discussed risks of bias and have implemented
tools to reduce these risks. There are additional challenges that
we anticipate with implementing the study procedure. First,
recruiting from one hospital can limit the representativeness
of our sample and can hamper the potential to gain the
optimal sample size. The institution where we will conduct
our trial covers the neurological rehabilitation of a substantial
part of the NZ population, which will ensure our sample is
largely representative for the region. We first want to ensure
the feasibility of our trial at this site before considering the
potential to extend the trial to at least one other site. With a
priori planned interim analyses, we will regularly check if the
conservative estimation of our optimal sample size will need
correction. Second, the design of our active control intervention
has several advantages mentioned above. Nonetheless, we have
to expect indirect therapeutic effects of our active control
treatment (e.g., incidental change in beliefs after re-establishing
a normal movement). Even accounting for the active control
treatment being potentially less effective than NH-CBT, it
seems likely that the mean difference between groups will be
small. Our power analysis therefore builds on a conservatively
estimated small between-group effect. When designing the

sample size of 164. A dropout rate of 5% is estimated based on our
clinical experience and a recently completed trial that evaluated
physiotherapy for individuals with FNSD (23). Accordingly a
sample size of 172 participants is planned to be recruited.
We will, however, allow eight interim analyses every 22nd
patient, conducted by a person who is independent of the day-today activities of the trial. Using the Lan-DeMets alpha spending
function (55) we have gained appropriate boundaries or p-values
for each interim analysis that would indicate a necessary stop
and would allow an early conclusion of the trial (see Table 3).
We used R 4.0.2 (56) and the ldbounds package (57) to gain
Lan-DeMets boundaries. This approach helps to control for
alpha-error accumulation with repeated interim analyses.

Statistical Analysis
Analyses will be based on intention-to-treat principles and will
be carried out at the end of the last follow-up assessment. We will
apply a linear mixed-effect model with baseline adjustment with
main effects (fixed effect) for time (level 1, contrasts to baseline
at 8- and 16-week follow-up) and group (level 2), group-by-time
cross-level interaction term (8- and 16-week follow-up), and a
generalized covariance matrix to account for dependency among
observations. In order to deal with missing values, maximum
likelihood estimation will be applied. Patterns of missing values
will be assumed to be random. The outcomes of interest will
be the group-by-time interaction at week 8 (hypothesis 1 and
2), and at week 16 (hypothesis 3). Effect sizes (Cohen’s d) with
95% CI of changes between baseline and 8- and 16-week followup, as well as of between-group differences at 8- and 16-week
follow-up will be investigated. Further sensitivity analyses will
be conducted depending on the dropout rates and pattern of
dropout reasons. For this purpose the linear mixed-effect models
described above will be rerun for defined subgroups of the total
sample (e.g., for participants with complete datasets only). To test
for moderation (exploratory research question) we will add the
moderator variable to the linear mixed-effect model described
above (level 1: time; level 2: group) and will analyze a 3-level
interaction. A significance level of 5% will apply to all analyses.
Statistical analyses will be conducted with SPSS.
A limitation of group analyses is that it provides no
information about the relative proportions of participants who
did or did not respond to a treatment, which is based on a set
standard. In accordance with recommendations by the Initiative
on Methods, Measurement, and Pain Assessment in Clinical
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control intervention, we also had to consider the pragmatic
fact that a treatment-as-usual or a waitlist control group would
not have been feasible, because our institution is the only one
covering neurorehabilitation for patients from a bigger district
in New Zealand, implying limited resources and long waitlists for
receiving treatment. Third, another pragmatic limitation is that
we have to accept participants in the inpatient and outpatient
settings as well as participants of older ages. We will apply
statistical strategies to control for the type of treatment setting
in our data analysis. We will include older participants only if
motor symptoms are considered highly likely to be functional
and not related to age-related degenerative processes. Fourth, our
8-week follow-up window after the end of treatment is very short.
Again, due to pragmatic reasons associated with delivering both
treatments in the context of a clinical service, we would not be
able to let our control participants wait for a longer period than
this before they receive NH-CBT. At the same time, we consider
the controlled follow-up assessment as an important strength of
our study design. Finally, we will implement several methods
to ensure treatment fidelity (e.g., frequent supervision, audiorecording the initial therapy session, and feedback to therapists).
However, we will not be able to completely exclude the risk
of therapists deviating from our rules of treatment fidelity and
exposing participants to distraction techniques or interventions
that address illness beliefs.
NH-CBT is a strongly theory-driven treatment concept,
combining the two first-line interventional approaches for
FNSD/PMD in a unique way. Its interdisciplinary character,
involving neurologists, clinical psychologists, physiotherapists,
occupational therapists, and other rehabilitation professionals
is in accordance with a biopsychosocial understanding of
persistent physical symptoms. This stands in contrast to a
more reductionistic biomedical model and arguably better
addresses the multidimensional etiopathogenesis of a complex
phenomenon such as functional motor symptoms. We see
much potential to improve the treatment outcome for patients
with complex conditions such as FNSD in formulating links
between different disciplines into a coherent, theory-driven,
truly interdisciplinary approach. Results from previous research
focusing on monodisciplinary approaches have not been
convincing. For example, a recently published RCT showed
no effect of a sophisticated CBT treatment for patients with
functional epileptic seizures on the frequency and severity
of seizures and mostly small effects on secondary outcomes
compared with a treatment as usual (59).
First results from a case series examining the effects of
NH-CBT show promising effects (27). The sensible next step
is to investigate the efficacy of NH-CBT in a randomized
trial and to gain knowledge about how well the intervention’s
effect can be sustained and by which variables it is moderated.
If demonstrated to have efficacy, we would then prioritize
an evaluation of its effectiveness and feasibility nationally
and internationally, with the aim of implementing NH-CBT
into routine practice worldwide. We anticipate challenges
associated with implementing an interdisciplinary treatment
that requires a whole team to be committed to a mutual
therapeutic understanding. However, the experience at the

Frontiers in Neurology | www.frontiersin.org

rehabilitation center where NH-CBT originated has been that
this was not a considerable impediment in the context of
an existing interdisciplinary approach to neurorehabilitation.
Countries such as New Zealand and Australia are often
progressive in implementing treatment for chronic conditions
in interdisciplinary treatment settings, e.g., the National Pain
Strategy in Australia (60). A successful trial has the capacity
to transform the lives of individuals living with functional
neurological symptoms and substantially reduce financial
burdens on healthcare systems around the world.
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